Xenikos develops immunotherapies based on toxin-conjugated monoclonal antibodies designed to reset the immune system in life‑threatening T cell–mediated conditions. Its flagship product, T‑Guard, targets CD3 and CD7 to selectively eliminate mature T cells and NK cells with a short-lived effect to reduce infection risk. A Phase 1/2 study showed a high complete response rate and a doubling of six‑month overall survival versus institutional historical controls; those results were published in a peer‑reviewed journal. T‑Guard has been granted Orphan Drug Designation in both the EU and the US. The company plans a randomized Phase 3 registrational trial in the US and EU to evaluate T‑Guard versus ruxolitinib for steroid‑refractory acute graft‑versus‑host disease, expected to commence in the second half of 2021. Xenikos is based in Nijmegen, the Netherlands, and recently secured financing to support the Phase 3 program. Xenikos is a Dutch biotech developing a late-stage transplantation medicine. Its core product is a transplantation treatment currently in late-stage development. The company secured $30 million in a Series B financing. Medicxi and RA Capital Management are named participants in the round. Proceeds are intended to push the transplantation medicine through further development. The article does not provide revenue, user metrics, prior fundraising details, or a founding year.

Total raised

$78M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Sep 2021